Savant Capital LLC Buys Shares of 29,088 Relay Therapeutics, Inc. (NASDAQ:RLAY)

Savant Capital LLC bought a new stake in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 29,088 shares of the company’s stock, valued at approximately $120,000.

Several other institutional investors also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC raised its holdings in Relay Therapeutics by 6.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 41,203 shares of the company’s stock valued at $292,000 after buying an additional 2,547 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Relay Therapeutics during the third quarter valued at about $63,000. China Universal Asset Management Co. Ltd. raised its holdings in Relay Therapeutics by 37.8% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 35,491 shares of the company’s stock valued at $146,000 after buying an additional 9,740 shares in the last quarter. Portland Investment Counsel Inc. bought a new position in shares of Relay Therapeutics in the third quarter worth about $71,000. Finally, XTX Topco Ltd increased its stake in shares of Relay Therapeutics by 27.9% in the third quarter. XTX Topco Ltd now owns 47,271 shares of the company’s stock worth $335,000 after purchasing an additional 10,311 shares during the period. 96.98% of the stock is currently owned by institutional investors.

Relay Therapeutics Stock Up 6.1 %

Shares of RLAY opened at $4.16 on Thursday. Relay Therapeutics, Inc. has a 12-month low of $3.50 and a 12-month high of $11.07. The firm has a market capitalization of $696.30 million, a price-to-earnings ratio of -1.59 and a beta of 1.61. The stock’s 50-day moving average price is $4.40 and its 200 day moving average price is $5.66.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the company. Leerink Partners dropped their price objective on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research note on Wednesday, December 4th. HC Wainwright reiterated a “buy” rating and issued a $16.00 price objective on shares of Relay Therapeutics in a research note on Tuesday, January 14th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $21.00 price objective on shares of Relay Therapeutics in a research note on Thursday, December 12th. One research analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Relay Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $20.50.

Insider Activity at Relay Therapeutics

In other Relay Therapeutics news, insider Peter Rahmer sold 32,156 shares of Relay Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $4.15, for a total transaction of $133,447.40. Following the sale, the insider now directly owns 357,507 shares of the company’s stock, valued at approximately $1,483,654.05. The trade was a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sanjiv Patel sold 100,000 shares of Relay Therapeutics stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $5.00, for a total value of $500,000.00. Following the sale, the chief executive officer now directly owns 574,548 shares in the company, valued at $2,872,740. The trade was a 14.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 570,152 shares of company stock worth $2,491,157 over the last three months. Company insiders own 4.32% of the company’s stock.

Relay Therapeutics Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.